Kyowa Kirin Co., Ltd. clinical trials

Also known as Kyowa Hakko Kirin.

Part of Kirin Holdings Company, Limited, which holds 55.17% as of 2026-03-19. Source

The registry lists 233 studies whose lead sponsor is Kyowa Kirin Co., Ltd. or one of 7 companies grouped under it. 13 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 26, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 233. Browse all 233 →

• A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin LymphomaRecruitingNCT07192471Phase 1

  Sponsor listed in the registry: Kyowa Kirin, Inc.

• A First-in-human Study of KK8123 in Adults With X-linked HypophosphatemiaRecruitingNCT06525636Phase 1/2
• A Phase 1/2 Study of KK2430 in Participants With Hematologic NeoplasmsRecruitingNCT07629726Phase 1/2
• Registry for Patients With X-Linked HypophosphatemiaRecruitingNCT03193476

  Sponsor listed in the registry: Kyowa Kirin Pharmaceutical Development Ltd · Kyowa Kirin Pharmaceutical Development Ltd — acquired company within the Kyowa Kirin Co., Ltd. group

• Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.RecruitingNCT06812104Phase 1
• Study of KK3910 in Healthy Volunteers and Patients With Essential HypertensionRecruitingNCT06823947Phase 1
• A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid LeukemiaRecruitingNCT07623616Phase 2
• A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid TumorsRecruitingNCT06248411Phase 1
• Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceRecruitingNCT07132567
• Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean PatientsRecruitingNCT06202027

  Sponsor listed in the registry: Kyowa Kirin Korea Co., Ltd.

• Expanded Access to BurosumabAvailableNCT03775187
• Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With MogamulizumabRecruitingNCT04014374

  Sponsor listed in the registry: Kyowa Kirin, Inc.

• Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea PatientsRecruitingNCT06186934

  Sponsor listed in the registry: Kyowa Kirin Korea Co., Ltd.

• A Study of KK2269 in Adult Participants With Solid TumorsActive, not recruitingNCT06266299Phase 1
• Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular EdemaActive, not recruitingNCT06116916Phase 2
• Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular DegenerationCompletedNCT06116890Phase 2
• Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）Active, not recruitingNCT06926491Phase 3
• Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)Active, not recruitingNCT04533581Phase 2
• A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus ErythematosusCompletedNCT05411016Phase 1
• A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic TherapyCompletedNCT06285370Phase 4

  Sponsor listed in the registry: Kyowa Kirin China Pharmaceutical Co., Ltd. · First submitted before Kyowa Kirin China Pharmaceutical Co., Ltd. left Kyowa Kirin Co., Ltd.

• Gene Therapy With Modified Autologous Hematopoietic Stem Cells for the Treatment of Patients With Mucopolysaccharidosis Type I, Hurler VariantActive, not recruitingNCT03488394Phase 1/2

  Sponsor listed in the registry: Orchard Therapeutics · First submitted before Orchard Therapeutics became part of Kyowa Kirin Co., Ltd.

• A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal GrowthCompletedNCT05181839

  Sponsor listed in the registry: Kyowa Kirin Pharmaceutical Development Ltd · Kyowa Kirin Pharmaceutical Development Ltd — acquired company within the Kyowa Kirin Co., Ltd. group

• Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)CompletedNCT05455931

  Sponsor listed in the registry: Kyowa Kirin Pharmaceutical Development Ltd · Kyowa Kirin Pharmaceutical Development Ltd — acquired company within the Kyowa Kirin Co., Ltd. group

• A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD)CompletedNCT03392987Phase 2

  Sponsor listed in the registry: Orchard Therapeutics · First submitted before Orchard Therapeutics became part of Kyowa Kirin Co., Ltd.

• A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCTActive, not recruitingNCT06149403Phase 3

  Sponsor listed in the registry: Orchard Therapeutics · First submitted before Orchard Therapeutics became part of Kyowa Kirin Co., Ltd.

• Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT03985189Phase 1
• Gene Therapy for Metachromatic Leukodystrophy (MLD)CompletedNCT01560182Phase 1/2

  Sponsor listed in the registry: Orchard Therapeutics · First submitted before Orchard Therapeutics became part of Kyowa Kirin Co., Ltd.

• Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic AnemiaActive, not recruitingNCT04870346
• OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD)Active, not recruitingNCT04283227Phase 3

  Sponsor listed in the registry: Orchard Therapeutics · First submitted before Orchard Therapeutics became part of Kyowa Kirin Co., Ltd.

• Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian PartnersActive, not recruitingNCT03745521
• A Phase 3 Study of KHK4827 in Patients With Systemic SclerosisCompletedNCT03957681Phase 3
• A Study of KHK4827 in Patients With Systemic SclerosisCompletedNCT04368403Phase 1
• Prebiotic Effects on Gut Microbiota, Gut Comfort and Immune FunctionActive, not recruitingNCT06094153Not applicable

  Sponsor listed in the registry: Kyowa Hakko Bio Co., Ltd. · First submitted after Kyowa Hakko Bio Co., Ltd. left Kyowa Kirin Co., Ltd.

• Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of AgeCompletedNCT04188964Phase 1/2

  Sponsor listed in the registry: Kyowa Kirin Pharmaceutical Development Ltd · Kyowa Kirin Pharmaceutical Development Ltd — acquired company within the Kyowa Kirin Co., Ltd. group

• A Study of KW-3357 in Congenital Antithrombin DeficiencyCompletedNCT00938288Phase 1
• Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung CancerCompletedNCT02358473Phase 1

  Sponsor listed in the registry: Kyowa Kirin, Inc.

• Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLHCompletedNCT02915705Phase 3

  Sponsor listed in the registry: Kyowa Kirin, Inc.

• Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 YearsWithdrawnNCT01596426Phase 1

  Sponsor listed in the registry: Kyowa Kirin Pharmaceutical Development Ltd · Kyowa Kirin Pharmaceutical Development Ltd — acquired company within the Kyowa Kirin Co., Ltd. group

• Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 YearsWithdrawnNCT01596413Phase 1

  Sponsor listed in the registry: Kyowa Kirin Pharmaceutical Development Ltd · Kyowa Kirin Pharmaceutical Development Ltd — acquired company within the Kyowa Kirin Co., Ltd. group

• A UK Multicentre, Health-Related Quality of Life Study for Children and Adolescents With XLHCompletedNCT04819490

  Sponsor listed in the registry: Kyowa Kirin Pharmaceutical Development Ltd · Kyowa Kirin Pharmaceutical Development Ltd — acquired company within the Kyowa Kirin Co., Ltd. group

• An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal GranisetronCompletedNCT00868764Phase 1
• Naloxegol Drug Utilization Post Authorisation Safety StudyCompletedNCT02813148

  Sponsor listed in the registry: Kyowa Kirin Pharmaceutical Development Ltd · Kyowa Kirin Pharmaceutical Development Ltd — acquired company within the Kyowa Kirin Co., Ltd. group

• Naloxegol Health Outcome Post Authorisation Safety StudyTerminatedNCT02813369

  Sponsor listed in the registry: Kyowa Kirin Pharmaceutical Development Ltd · Kyowa Kirin Pharmaceutical Development Ltd — acquired company within the Kyowa Kirin Co., Ltd. group

• Study of Romiplostim(AMG531) in Subjects With Aplastic AnemiaCompletedNCT02773290Phase 2/3
• A Study of Brodalumab in Subjects With Axial Spondyloarthritis (axSpA)CompletedNCT02985983Phase 3
• Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIOCompletedNCT05357573Phase 4
• Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLHCompletedNCT04842019Phase 4
• Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLHCompletedNCT04842032Phase 4
• Safety Study of AMG 531 in Japanese Subjects With ITPCompletedNCT00305435Phase 2
• Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)CompletedNCT02537431Phase 3

  Sponsor listed in the registry: Kyowa Kirin, Inc.